Trial Profile
ABX209: Phase II Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Jan 2019
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Carboplatin; Gemcitabine
- Indications Urogenital cancer
- Focus Therapeutic Use
- 10 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 08 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Dec 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.